Cynata Therapeutics Limited EBIT

Cynata Therapeutics Limited (CYYNF) currently reports a EBIT of $-19M as of June 2026. That compares with $-29M in the prior-year period — up 34.1% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore Cynata Therapeutics Limited's EBIT history and peer comparisons.

Cynata Therapeutics Limited's EBIT increased from $-29M to $-19M — a 34.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cynata Therapeutics Limited's EBIT of $-19M is lower than the Healthcare sector average of $130B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Cynata Therapeutics Limited reported $-19M in EBIT as of June 2026. That compares with $-29M in the prior-year period — up 34.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-19M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for Cynata Therapeutics Limited, and consider following CYYNF for alerts when major investors trade the stock.